HONG KONG – China's leading contract research organization (CRO), Wuxi Apptec Co. Ltd., is set to debut on the Shanghai Stock Exchange via a $910 million IPO for its core small-molecule CRO business.

HONG KONG – Adagene Inc., of Suzhou, China, raised $50 million in series C financing to push its antibody candidates, already in the process of investigational new drug (IND) filings, closer to clinical studies in China and the U.S.

HONG KONG – Adagene Inc., of Suzhou, China, raised $50 million in series C financing to push its antibody candidates, already in the process of investigational new drug (IND) filings, closer to clinical studies in China and the U.S.